NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer - NeLM

NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer - NeLM

The consultation period closes on 22 February 2013

NeLM news service

NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer

Source: NICE

Date published: 01/02/2013 17:26

Summary

by: Angela Bennett

The National Institute for Health and Clinical Excellence (NICE) has issued for consultation an Appraisal Consultation Document (ACD) on the use of bevacizumab for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease).

The following preliminary recommendations have been made:


• Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).

• People currently receiving bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer should be able to continue treatment until they and their clinician consider it appropriate to stop.

The consultation period closes on 22 February 2013